Skip to main content

Table 3 AUC improvements relative to placebo

From: Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

Assessment Parameter PBO MEM PBO-DON MEM-DON
  number = 281 number = 289 number = 418 number = 429
SIB AUC0-24 a −51.4 ± 10.9 4.9 ± 10.5 27.5 ± 8.6 67.4 ± 8.3
│Xb - PBO│c 0 56.3* 78.9*** 118.8***
│Xb - PBO│/│PBO│, % - 109.6 153.5 231.1
ADCS-ADL19 AUC0-24 a −32.7 ± 6.4 −12.2 ± 6.2 −9.5 ± 5.0 1.4 ± 4.9
│Xb - PBO│c 0 20.5 23.3* 34.2***
│Xb - PBO│/│PBO│, % - 62.6 71.1 104.4
NPId AUC0-24 a 22.4 ± 12.2 −7.3 ± 11.8 −27.2 ± 9.7 −74.3 ± 9.4
│Xb - PBO│c 0 29.8 49.6** 96.8***
│Xb - PBO│/│PBO│, % - 132.5 221.0 431.2
CIBIC-Plus AUC0-24 a 6.0 ± 1.1 2.0 ± 1.0 1.4 ± 0.9 −2.1 ± 0.8
│Xb - PBO│c 0 4.0 4.6* 8.1***
│Xb - PBO│/│PBO│, % - 65.9 76.2 135.6
4D-CI AUC0-24 a −175.4 ± 63.7 152.1 ± 61.5 344.7 ± 50.4 630.0 ± 49.0
│Xb - PBO│c 0 327.4** 520.0*** 805.4***
│Xb - PBO│/│PBO│, % - 186.7 296.6 459.3
  1. aMean ± SE (point x week); bany active treatment group; cmean (point x week); dfor NPI, lower score indicates improvement. *P <0.05; **P <0.01; ***P <0.001. 4D-CI, four-dimensional composite index; ADCS-ADL19, 19-item Alzheimer’s Disease Cooperative Study – Activities of Daily Living scale; AUC, area under the curve; CIBIC-Plus, Clinician’s Interview-Based Impression of Change – Plus Caregiver Input; MEM, memantine; MEM-DON, memantine added to background donepezil treatment; NPI, Neuropsychiatric Inventory; PBO, placebo; PBO-DON, placebo added to background donepezil treatment; SE, standard error of the mean; SIB, Severe Impairment Battery.